Financial PositionVoyager's cash position of $295M is projected to fund operations into mid-2027, indicating potential value creation from clinical advancement and partnerships.
Partnership MilestonesVoyager could realize up to $35MM in regulatory and clinical milestones related to the FXN/GBA1 programs, enhancing its financial outlook.
Pipeline ProgressVoyager's tau-targeting Alzheimer's programs and partnered gene therapy pipeline are showing continued progress, with key milestones expected over the next several months.